Trinity Biotech (TRIB) Cash from Financing Activities (2009 - 2024)

Trinity Biotech has disclosed Cash from Financing Activities across 16 years of filings, most recently posting $1.8 million for Q4 2024.

• In Q4 2024, Cash from Financing Activities rose 202.21% year-over-year to $1.8 million; the TTM figure through Dec 2024 stood at $28.8 million (up 279.59% YoY), while the FY2025 annual figure was $12.1 million, down 58.17% from the prior year.
• Cash from Financing Activities came in at $1.8 million for Q4 2024 at Trinity Biotech, down from $4.2 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $18.8 million in Q1 2024 to a low of -$13.5 million in Q2 2023.
• Average Cash from Financing Activities over 5 years is -$983850.0, with a median of -$2.0 million recorded in 2020.
• Year-over-year, Cash from Financing Activities tumbled 486.16% in 2022 and surged 1072.01% in 2024.
• Over 5 years, Cash from Financing Activities stood at -$3.6 million in 2020, then gained by 0.77% to -$3.6 million in 2021, then soared by 48.56% to -$1.8 million in 2022, then grew by 4.28% to -$1.8 million in 2023, then surged by 202.21% to $1.8 million in 2024.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $1.8 million in Q4 2024, $4.2 million in Q3 2024, and $3.9 million in Q2 2024.